Login and fund life
Clinical studies show after 6 months of trying to conceive 75% of women have an ovulatory issue resulting in variable ovulation. OvuSense solves this problem by predicting ovulation 24 hours in advance using data from the current cycle which is not affected by this variability.
CE and FDA 510(k) approved as a medical device; with a portfolio of 9 patents; 5 clinical publications; and a proven business model, OvuSense™ is the only fertility monitor capable of:
The company was transformed in 2014 to sell OvuSense directly to the consumer via the company's dedicated ecommerce platform. An App version of the product was launched in 2016 and with over 3,500 customers in UK and USA.
With all technology, clinical and regulatory risks removed and the business model proven, the company is now seeking £1m growth capital to take the business to breakeven.
Rob has over 26 years experience in financing and bringing ground-breaking medical technology and software to global markets, with the past 15 years focused on women’s health. He is also CEO of Fertility Focus Inc., the company’s wholly owned US subsidiary. Robert has worked for Roche, Oxford Instruments, and was formerly a member of the Operations Board of Huntleigh Healthcare following the successful sale and integration of the Sonicaid Fetal Monitoring and Medilog Cardiology businesses. He brings additional extensive experience in general management, sub-contract manufacturing, sales and marketing & M&A.
Share this project in your website. Copy and paste the following code in your content